{"analyses":[{"ciLowerLimit":"0.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.76","groupDescription":"At CCOD 18 months; Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0026","paramType":"Hazard Ratio (HR)","paramValue":"0.44","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.35","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.80","groupDescription":"At CCOD 30 months; Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0019","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG000","lowerLimit":"6.74","upperLimit":"NA","value":"11.37"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"13.50","upperLimit":"NA","value":"NA"}]}],"title":"At CCOD 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.74","upperLimit":"16.07","value":"11.37"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"17.12","upperLimit":"NA","value":"24.05"}]}],"title":"At CCOD 30 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - China"},{"description":"Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - China"}],"paramType":"MEDIAN","populationDescription":"China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.","reportingStatus":"POSTED","timeFrame":"From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)","title":"Overall Survival (OS) in the China Population","type":"PRIMARY","unitOfMeasure":"months"}